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Introduction: Anxiety and mild cognitive impairment (MCI) are prevalent non-motor manifestations of
Parkinson's disease (PD). While few studies have demonstrated a possible link between cognitive
dysfunction and anxiety in PD, to our knowledge, no studies have directly examined the association
between them. This study investigated the association between anxiety and cognitive deﬁcits in newly
diagnosed PD patients.
Methods: Patients with newly diagnosed PD (N ¼ 185) were recruited from community and outpatient
clinics. Anxiety was assessed using the Uniﬁed Parkinson's Disease Rating Scale (MDS-UPDRS) clinician
rated anxiety item, which has previously been validated against a standardized criteria for the diagnosis
of anxiety disorders in PD. Participants scoring 2 were classiﬁed as anxious. A threshold of 1 SD below
normative values (obtained from controls) was used to deﬁne cognitive impairment. Impairments in
speciﬁc cognitive domains were identiﬁed as being >1 SD below controls in 1 test per domain.
Results: After controlling for age, education and motor severity, patients with anxiety were three times
more likely to have cognitive impairment compared to those without anxiety (OR ¼ 3.0, 95% CI ¼ 1.2e7.3,
p < 0.05). Patients with anxiety were more than twice as likely to be classiﬁed as having cognitive
impairment due to impairment in the memory domain compared with PD without anxiety (OR ¼ 2.3,
95% CI ¼ 1.0e5.1, p < 0.05), whilst no associations were found between anxiety and performance on
other cognitive domains.
Conclusion: This study shows an association between anxiety and cognitive impairment (speciﬁcally
memory impairment). Examining the neural basis of this association warrants future research in this
developing ﬁeld.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Anxiety and mild cognitive impairment (MCI) are common in
Parkinson's disease (PD) [1]. A recent systematic review estimatedland, UQ Centre for Clinical
Hospital, Herston QLD 4029,
Dissanayaka).
r Ltd. This is an open access articlethat the prevalence of anxiety in PD to be 31%, based on the
Diagnostic and Statistical Manual of Psychiatric Disorders (DSM)
criteria or scoring above thresholds on validated rating scales [2].
Cognitive deﬁcits are also commonly observed at the time of PD
diagnosis, with many patients ultimately developing dementia [3].
Mild cognitive impairment in PD (PD-MCI) may represent a tran-
sitional state between a cognitively intact stage and dementia
(PDD) [4].
Studies examining the association between anxiety and PD-MCIunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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directly examined the relationship between these two primary
neuropsychological complaints in newly diagnosed PD patients.
Such an approach would be useful in the clinical management of
these non-motor symptoms and the identiﬁcation of neuropsy-
chological subtypes in PD. It has been suggested that cognitively
impaired PD patients are more likely to use anti-anxiety medica-
tion than those without [5] and that pharmacological treatment of
PD-MCI using rivastigmine has been shown to reduce concomitant
anxiety [6].
A few studies have demonstrated a possible link between
cognitive dysfunction and anxiety in PD [7e11], although none
directly investigated this association nor examined the interde-
pendence between anxiety and cognitive subtypes in PD. This study
investigated the role of anxiety in cognitive impairment, and spe-
ciﬁcally, the cognitive domains affected in this latter state in newly
diagnosed PD. It was hypothesised that anxiety is associated with
cognitive impairment based on studies in older adults [12,13] with
impairments in memory and executive functioning being those
domains most positively associated with anxiety.
2. Methods
2.1. Participants
Newly diagnosed PD patients were recruited as part of the
Incidence of Cognitive Impairment in Cohorts with Longitudinal
Evaluation in Parkinson's Disease (ICICLE-PD) study [14]. PD pa-
tients were recruited from community and outpatient clinics in
Newcastle-upon-Tyne, Gateshead and Cambridgeshire, UK. Inclu-
sion criteria involved having a diagnosis of idiopathic PD according
to the Queen's Square Brain Bank Criteria [15] between 1st June
2009 and 31st December 2011. Exclusion criteria comprised: sig-
niﬁcant cognitive impairment as deﬁned by scoring <24 in the Mini
Mental State (MMSE) or a pre-existing diagnosis of dementia,
insufﬁcient command of the English language to complete assess-
ments, dementia with Lewy bodies (DLB), parkinsonism due to
another cause, drug-induced parkinsonism, progressive supra-
nuclear palsy, multiple system atrophy or corticobasal
degeneration.
Normative data for neuropsychological assessments was pro-
vided from age-matched healthy control subjects (n ¼ 99). Carers
and spouses were not recruited as control subjects in order to
minimize potential bias. Controls were recruited from the general
population in the North East of England through local advertising
and community to ensure controls were unrelated to PD
participants.
This study was approved by the NHS Local Research Ethics
Committee, Newcastle and North Tyneside 1. All participants gave
written informed consent prior to study inclusion.
2.2. Assessments
Demographic information, including age, sex and education,
was collected. All subjects underwent a medical assessment, which
included an interview with a movement disorders specialist. De-
tails of disease duration from diagnosis, level of education, co-
morbidities, and medication use were recorded. All patients with
PD on antiparkinsonian medications were evaluated in the “on”
motor state; this was determined by the researcher and from
asking participants about their response to antiparkinsonian
medication. Motor disability and disease severity were rated with
the MDS revised Uniﬁed Parkinson's Disease Rating Scale (MDS-
UPDRS) part III and Hoehn and Yahr scale, respectively [16,17].
Levodopa equivalent dose (LED) was calculated for alldopaminergic medications using the conversion factors outlined by
Tomlinson et al. [18].
Participants completed the National Adult Reading Test (NART)
[19] as a measure of pre-morbid IQ, and the Geriatric Depression
Scale (GDS-15) [20]. Anxiety was assessed using the anxiety item
from the MDS-UPDRS [17]. This clinician-rated anxiety assessment
has been recently validated against DSM-IV criteria for anxiety
disorders with high validity (area under the Receiver Operating
Characteristic curve was 0.94 and suggested an optimal cut-off
score of 2) (unpublished data. Doctor of Psychology thesis
completed by Elizabeth Torbey and supervised by Dissanayaka.
Manuscript is currently in preparation). Participants were classiﬁed
as anxious if they scored 2.
2.3. Neuropsychological testing
Participants completed a schedule of neuropsychological tests
across ﬁve cognitive domains. Global cognitive function was
assessed with the MMSE [21] and Montreal Cognitive Assessment
(MoCA) [22]. Attention was measured using Power of Attention
(PoA) and Digit Vigilance Accuracy from the Cognitive Drug
Research (CDR) battery [23]. PoA is a composite score of Simple
Reaction Time, Choice Reaction Time and Digit Vigilance reaction; a
higher score indicating greater impairment. Memory was assessed
using Pattern Recognition Memory (PRM), Spatial Recognition
Memory (SRM) and Paired Associates Learning (PAL) from the
computerised Cambridge Neuropsychological Test Automated
Battery (CANTAB) [24]. Executive function was determined using
the One Touch Stockings (OTS) task from the CANTAB [24], pho-
nemic ﬂuency (words beginning with F in one minute) [25] and
semantic ﬂuency (naming animals in 90 s) [26]. As a measure of
visuospatial function the pentagon copying item of the MMSE was
graded using a modiﬁed 0e2 rating scale [27]. Language was
assessed using the naming (0e3) and sentence (0e2) subsets from
the MoCA.
Participants were classiﬁed as having PD-MCI using modiﬁed
Level II MDS criteria [28], as our schedule of neuropsychological
tests preceded these criteria, as described previously [14]. PD-MCI
participants were impaired in at least two neuropsychological
tests, either on two tests within one cognitive domain, or at least
one test in more than one domain. Subjective cognitive and func-
tional independence of the participants was determined through
semi-structured interviews with participants and/or their carers.
MDS criteria speciﬁes impairment should be between 1 and 2 SD
below normative values; as this was an exploratory analysis in
newly-diagnosed patients, 1SD, 1.5SD and 2SD below normative
values (controls) were each used as cut-offs for PD-MCI. Partici-
pants with PD-MCI were further classiﬁed by impairments in spe-
ciﬁc cognitive domain, determined by > 1SD, >1.5SD or >2SD, as
appropriate, below controls in 1 test per domain, in keeping with
PD-MCI criteria [28].
2.4. Analysis
Statistical analyses were performed using SPSS (Version 21.0;
SPSS, Inc., Chicago, IL). Data were examined for normality of dis-
tributionwith visual histograms and the Kolmogorov-Smirnov test.
Comparison of means between the two groups was performed
using independent t-tests or Mann-Whitney U-tests, as appro-
priate. For comparisons of more than two groups, one-way ANOVA
or Kruskal-Wallis tests were used as appropriate. Chi-squared tests
were used to assess binary outcome variables. The signiﬁcance level
for all statistical testswas set at a¼ 0.05 (two-tailed). As this was an
exploratory study, corrections for multiple comparisons were not
made.
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dictors of PD-MCI. Backwards stepwise logistic regressionwas used
to produce a basic model of predictors involving: age, sex, years of
education, LED, GDS-15 and MDS-UPDRS III. Non-continuous data
were dichotomised using the median. Non-signiﬁcant predictors
were excluded. Signiﬁcant predictors were then included and
anxiety was added to the model.Table 2
Regression coefﬁcients of predictors of cognitive impairment.
b SE p OR 95% CI for OR
Lower
Bound
Upper
Bound
Univariate analysis
Age 0.1 0.0 <0.001 1.1 1.1 1.1
Sex (male) 0.5 0.3 0.120 1.6 0.9 3.1
Education 1.5 0.3 <0.001 0.2 0.1 0.4
MDS-UPDRS III 0.1 0.0 <0.001 1.1 1.0 1.1
LEDD (mg/d) 0.0 0.0 0.941 1.0 1.0 1.0
GDS-15 0.5 0.4 0.208 1.6 0.8 3.3
Anxiety 0.8 0.4 0.035 2.3 1.1 5.0
Full model
Age 0.1 0.0 <0.001 1.1 1.1 1.1
Education 1.0 0.4 0.007 2.7 1.3 5.5
MDS-UPDRS III 0.1 0.0 0.001 1.1 1.0 1.1
Anxiety 1.1 0.5 0.015 3.0 1.2 7.3
Signiﬁcant results highlighted in bold.
Cognitive impairment in Parkinson's disease using the 1 SD cut-off, MDS-UPDRS
III ¼ Movement Disorders Society-Uniﬁed Parkinson's Disease Rating Scale Part III,3. Results
Two hundred and nineteen participants completed assess-
ments; subsequently seven participants were re-diagnosed as not
having idiopathic PD and were excluded from any further analyses.
A further 27 participants did not complete the anxiety item of the
MDS-UPDRS as it was introduced after the study had commenced
and were excluded from the analysis, leaving 185 PD participants.
Participants had a mean disease duration of 5.6 ± 5.2 months; 17%
(n ¼ 32) of participants were drug naïve (Table 1). 21% (n ¼ 41) of
participants were prescribed anxiolytics and/or antidepressants,
comprising: 8% (n ¼ 15) tricyclics, 6% (n ¼ 11) selective serotonin
reuptake inhibitors (SSRIs), 3% (n ¼ 6) benzodiazepines, 2% (n ¼ 3)
serotonin-norepinephrine reuptake inhibitors (SNRIs), 1% (n ¼ 2)
mirtazapine; and 3% (n ¼ 3) were prescribed more than one
medication from these groups.
Participants with anxiety (25%) were compared to participants
without anxiety (Table 1). Compared to patients without anxiety,
anxious PD patients were signiﬁcantly younger (62.2 ± 8.7 vs.
67.2 ± 3.2, p < 0.01), had higher LED (231.1 ± 192.6 vs. 165.2 ± 145.1,
p < 0.05) and GDS-15 scores (4.1 ± 3.2 vs. 2.5 ± 2.2, p < 0.01). There
were no signiﬁcant differences in disease duration, motor severity,
years of education, NART score, global cognition or use of anxio-
lytics and/or antidepressants between anxious and non-anxious PD
patients (p > 0.05, for all). There were no signiﬁcant differences in
the neuropsychological scores of participants with anxiety and on
treatment with anxiolytics and/or antidepressants compared to
those not in receipt of such medications (Supplementary Table 1).
Chi-squared tests showed that there were signiﬁcantly more
anxious participants with cognitive impairment using the 1SD cut-Table 1
Demographic and clinical characteristics of participants.
Total cohort
n ¼ 185
Anxiou
n ¼ 47
Mean SD Mean
Age, years 65.9 9.5 62.2
Education, years 12.9 3.6 12.9
NART 114.1 10.5 112.7
PD duration (months) 5.6 5.2 5.6
UPDRS III 27.9 12.1 30.8
Hoehn and Yahr 1.9 0.6 1.8
LED (mg/d) 182.0 160.5 231.1
GDS-15 2.9 2.7 4.1
MoCA 25.4 3.4 25.8
MMSE 28.7 1.3 28.7
n % n
Sex (male) 117 63.2 27
Cognitive impairment 1SD 122 65.9 37
PD-MCI 1.5SD 79 42.7 20
PD-MCI 2SD 39 21.1 9
Anxiolytics and/or antidepressant use 41 22.1 15
PD drug naive 32 17.3 4
SD ¼ Standard deviation, NART ¼ National Adult Reading Test, UPDRS III ¼ Movement
equivalent dose, GDS-15 ¼ Geriatric Depression Scale, MoCA ¼ Montreal Cognitive
impairment in Parkinson's disease.
a Independent t-test.
b Mann-Whitney U test.off than non-anxious participants (78.7% vs. 61.6%, p < 0.05).
However, there were no signiﬁcant differences using the 1.5SD or
2SD cut-off (p > 0.05, Table 1).3.1. Predicting cognitive impairment
Univariate predictors of PD-MCI were determined using logistic
regression. Age, fewer number of years in education and increased
motor severity were signiﬁcant predictors of cognitive impairment
at 1SD (p < 0.001 for all, Table 2). Univariate analysis showed that
newly diagnosed PD participants with anxiety were more than
twice as likely to have cognitive impairment at 1SD (OR ¼ 2.3, 95%
CI ¼ 1.1e5.0, p < 0.05). Hierarchical regressionwas used to produce
a basic model. Consistent with the univariate analysis, age, educa-
tion and motor severity were signiﬁcant predictors of cognitive
impairment after non-signiﬁcant predictors were removed. Adding
anxiety status to the model revealed that it was a signiﬁcants Non-anxious
n ¼ 138
Anxious vs. Non-
anxious
SD Mean SD t/Z p
8.7 67.2 9.4 3.2a 0.002
3.5 12.9 3.7 0.0b 0.963
9.8 114.6 10.8 1.6b 0.109
5.3 5.6 5.1 0.8b 0.937
12.9 27.0 11.7 1.7b 0.095
0.6 1.9 0.6 0.7b 0.507
192.6 165.2 145.1 2.1b 0.033
3.2 2.5 2.4 3.2b 0.002
2.6 25.3 3.7 0.2b 0.862
1.3 28.7 1.3 0.2b 0.868
% n % c2 p
57.4 90 65.2 0.9 0.340
78.7 85 61.6 4.6 0.032
42.6 59 42.8 0.0 0.981
19.1 30 21.7 0.1 0.707
31.2 26 18.8 3.5 0.062
8.5 28 20.3 3.4 0.065
Disorders Society-Uniﬁed Parkinson's Disease Rating Scale Part III, LED ¼ Levodopa
Assessment, MMSE ¼ Mini-Mental State Examination, PD-MCI ¼ Mild cognitive
LEDD ¼ Levodopa equivalent daily dose, GDS-15 ¼ Geriatric Depression Scale,
SE ¼ Standard error, OR ¼ Odds ratio, CI ¼ Conﬁdence interval.
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anxiety were three times more likely to have cognitive impairment
at 1SD compared to PD patients without anxiety, even after con-
trolling for age, education and motor severity (OR ¼ 3.0, 95%
CI ¼ 1.2e7.3, p < 0.05). However, anxiety was not a signiﬁcant
predictor when using the 1.5SD or 2SD cut off for PD-MCI
(Supplementary Table 2).
To determine whether anxiety was associated with particular
domains of cognitive impairment, hierarchical logistic regression
was used. Backwards regression was used to determine a basic
model for each of the ﬁve cognitive domains and non-signiﬁcant
predictors were excluded; anxiety status was then added by
forced entry (Table 3). PD patients with anxiety were more than
twice as likely to be classiﬁed as having cognitive impairment at 1
SD with impaired memory (OR ¼ 2.3, 95% CI ¼ 1.0e5.1, p < 0.05).
However, there was no signiﬁcant association with anxiety and the
other cognitive domains (p > 0.05). This analysis was repeated with
cognitive impairment as deﬁned using 1.5SD and 2SD cut-offs; and
no signiﬁcant association with anxiety was found (Supplementary
Table 3).4. Discussion
To the best of our knowledge, the present study is the ﬁrst to
directly focus on a relationship between anxiety, cognitive
impairment and cognitive subtypes in PD in a large cohort of newly
diagnosed patients. In our incident PD sample, patients with anx-
iety were three times more likely to present with cognitive
impairment at 1SD than patients without anxiety. However, this
result did not persist when more stringent cut-offs were applied.
These results are in line with previous studies that have
focussed on cognition in PD and evaluated anxiety as a secondary
measure. Using the brief Neuropsychological Inventory to assessTable 3
Regression coefﬁcients of predictors of impaired cognitive domains.
b SE p OR 95% CI for OR
Lower
Bound
Upper
Bound
Attention (n ¼ 78)
Age 0.1 0.0 0.003 1.1 1.0 1.1
Education (years) 0.9 0.3 0.007 0.4 0.2 0.8
MDS-UPDRS III 0.0 0.0 0.074 1.0 1.0 1.1
Anxiety 0.3 0.4 0.433 1.4 0.6 2.9
Memory (n ¼ 89)
Age 0.1 0.0 0.005 1.1 1.0 1.1
Education (years) 0.5 0.3 0.108 0.6 0.3 1.1
MDS-UPDRS III 0.1 0.0 0.001 1.1 1.0 1.1
Anxiety 0.8 0.4 0.041 2.3 1.0 5.1
Executive function (n ¼ 94)
Age 0.1 0.0 0.001 1.1 1.0 1.1
Education (years) 1.2 0.3 0.001 0.3 0.2 0.6
MDS-UPDRS III 0.0 0.0 0.029 1.0 1.0 1.1
Anxiety 0.2 0.4 0.713 1.2 0.5 2.6
Visuospatial function (n ¼ 24)
Age 0.1 0.0 0.007 1.1 1.0 1.1
MDS-UPDRS III 0.1 0.0 0.001 1.1 1.0 1.1
Anxiety 0.1 0.6 0.888 0.9 0.3 2.9
Language (n ¼ 55)
Education (years) 1.3 0.3 <0.001 0.3 0.1 0.5
Anxiety 0.2 0.4 0.545 1.3 0.6 2.6
Initial covariates included in each model: age, sex, education, MDS-UPDRS III, LEDD,
GDS-15.
Signiﬁcant results highlighted in bold.
Cognitive impairment in Parkinson's disease using the 1 SD cut-off, MDS-UPDRS
III ¼ Movement Disorders Society-Uniﬁed Parkinson's Disease Rating Scale Part III,
LEDD ¼ Levodopa equivalent daily dose, GDS-15 ¼ Geriatric Depression Scale,
SE ¼ Standard error, OR ¼ Odds ratio, CI ¼ Conﬁdence interval.anxiety, Monastero et al. [11] suggested a positive association be-
tween anxiety and PD-MCI in a sample of 410 non-demented PD
patients. In a recent smaller study of 40 patients, it was demon-
strated that anxiety, as assessed using the Hospital Anxiety and
Depression Scale, was associated with subjective cognitive com-
plaints in PD [10]. A further study showed an association between
cognitive clusters and avoidance anxiety using the new and vali-
dated Parkinson's Anxiety Scale (PAS), which was not available
during the data collection phase of our study [7]. The study aimed
to identify cognitive clusters to demonstrate the severity of
cognitive impairment in PD, but the authors did not relate anxiety
to a speciﬁc cognitive cluster or domain.
Another novel aspect of the present study is the investigation of
the relationship between anxiety and cognitive domains in PD. We
found that anxiety was associated with memory impairment using
the 1SD cut-off for cognitive impairment, but not with other cut-
offs. An association between anxiety and memory problems has
been previously reported in community dwelling older adults
without PD [12,13]. The study by Yochim et al. [13] suggested an
association between anxiety and semantic memory using the Cal-
ifornia Verbal Learning Test in 120 older adults. Beaudreau and
O'Hara [12] demonstrated a relationship between anxiety and
depression, and both episodic memory and semantic memory as
assessed using the Rey Auditory Verbal Learning test and Boston
Naming Test second edition, respectively. Memory components
assessed in the present study were Pattern Recognition Memory,
Spatial Recognition Memory and Paired Associates Learning using
CANTAB. Although depression often coexists with anxiety [29], our
results did not demonstrate an association between depression and
cognitive impairment in general or in relation to a speciﬁc subtype.
Our ﬁndings suggest that the presence of anxiety may have prog-
nostic signiﬁcance in determining which individuals are more
likely to develop PDD, and examining the underlying neural basis
for this association warrants future study.
Contrary to previous studies [12,13], the present study did not
demonstrate a relationship between anxiety and executive
dysfunction in PD. Yochim et al. [13] suggested such an association,
and similarly, Beaudreau and O'Hara [12] demonstrated that anxi-
ety is related to poor performance on a number of executive tasks.
Teasing this apart is difﬁcult, as anxiety can affect performance on
cognitive tasks without their being an actual cognitive deﬁcit.
Future investigations are required to identify the relationship be-
tween anxiety in PD and other executive functions.
Limitations of the present study should be noted. Firstly,
although validated, our deﬁnition of anxiety using the clinician
rated MDS-UPDRS anxiety item was brief. We did not make a
diagnosis of speciﬁc anxiety disorders based on criteria such as the
DSM-5 or the PAS as our study design preceded the development of
the PAS. Future studies investigating the relationship between PD-
MCI and anxiety subtypes should consider using these measures.
Secondly, we used modiﬁed MDS criteria for PD-MCI as our study
predated guidelines, with an unequal number of neuropsycholog-
ical tests per domain; this included more than two tests for
memory and executive function and only one test for visuospatial
function. This has implications for allowing us to accurately sub-
type patients' cognitive impairment, and may also increase the
frequency of impairments in some domains. Finally, we did not
observe signiﬁcant ﬁndings when using 1.5 or 2SD for PD-MCI. It is
likely that the smaller number of participants identiﬁed at being
impaired at this level reduced the statistical power to detect such
an association. Thus the data reported here should be viewed as
being exploratory and requires conﬁrmation in a larger cohort.
Whilst increased awareness of cognitive deﬁcits is likely to
exacerbate anxiety in PD patients [29], a recent prospective study
demonstrated that anxiety and MCI cluster together [8]. The
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poorer prognosis in terms of cognitive decline and non-motor
symptoms, including anxiety, at 4.5 years follow-up. Cognitive
dysfunction is irreversible in many cases, however, anxiety is
treatable [30] and thus treating it could potentially reduce or delay
the onset of cognitive impairment in PD. Therefore, understanding
the speciﬁc cognitive domains associatedwith anxietymay assist in
the development of tailored therapies for anxious PD patients
afﬂicted by coexisting cognitive deﬁcits. Longitudinal and neuro-
imaging studies are also required to advance our understanding of
the contribution of anxiety to the onset of cognitive deﬁcits, pro-
gression of PD and the neurobiological basis of these relationships.
Such approaches may assist in the identiﬁcation of early markers
for prodromal dementia in PD.
In conclusion, the present study demonstrated a positive asso-
ciation between anxiety and cognitive impairment in PD, in
particular memory deﬁcits. A more comprehensive examination of
the association between anxiety subtypes and cognitive domains
now merits further research.
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